MFS
DSGN icon

Mirabella Financial Services’s Design Therapeutics DSGN Stock Holding History

Mirabella Financial Services’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,814
Closed -$126K – 818
2026
Q1 		$126K Buy
+11,814
New +$120K 0.01% 844

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Mirabella Financial Services's DSGN Position: Q2 2026 in Review

Mirabella Financial Services sold out of Design Therapeutics (DSGN) in Q2 2026, closing a stake of 11,814 shares — an estimated $126K sold.

Mirabella Financial Services first reported a position in DSGN in Q1 2026 and held it in 1 quarter. The position peaked at $126K in Q1 2026. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Mirabella Financial Services reported no remaining Design Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Mirabella Financial Services sold 11,814 Design Therapeutics shares in Q2 2026, an estimated $126K.
  • Mirabella Financial Services first reported a position in Design Therapeutics in Q1 2026 and held it in 1 quarter.
  • Mirabella Financial Services's Design Therapeutics position peaked at $126K in Q1 2026.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Mirabella Financial Services's 13F filing for Q2 2026, filed 31 Jul 2026.